Presented by Dr. Giovanni Amoroso During the New Solutions for Serious Needs Session of EuroPCR
PARIS, FRANCE / ACCESSWIRE / May 23, 2019 / IdaHealth, a medical device company dedicated to modernizing proactive patient care through innovative monitoring systems, today introduced the company’s Radial Occlusion Artery Monitoring (ROAM) technology, IdaFlo Tr, during a presentation at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris. IdaFlo Tr is an innovative transradial nanotechnology-based bracelet that allows for the continuous, real-time and wireless monitoring of radial arterial blood flow.
Click here to view the full press release, including media-ready images, downloadable resources, and more.
About IdaHealth
IdaHealth is medical device company that designs, manufactures and markets non invasive disruptive predictive monitoring solutions that provide continuous information to proactively improve quality of life.
It is IdaHealth’s vision to becoming the leader of creating and delivering disruptive solutions that change the standard of care for non invasive and predictive monitoring systems to enhance quality of life. Using IdaHealth’s patented technology, the company is developing its first two breakthrough products.
IdaHealth delivers solutions that simply do not exist today.
Media Relations
David Camp Jr
Email: david@idahealth.com
Tel: (954) 806-2962
SOURCE: IdaHealth
View source version on accesswire.com:
https://www.accesswire.com/546241/IdaHealth-Showcases-Technology-to-Standardize-Radial-Occlusion-Artery-Monitoring-at-EuroPCR-2019
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…
The AI-enabled clinical assistant is available to query patient data across the EHR as well…
33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC)…
First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep,…
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase…
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="421px" width="388px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="600px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
